Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics
A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects With Type 2 Diabetes
Sponsor: Takeda
Listed as NCT00707993, this PHASE3 trial focuses on Diabetes Mellitus and remains completed. Sponsored by Takeda, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jun 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aguascalientes, Mexico, Aiken, United States, Albuquerque, United States, Alexander City, United States, Arequipa, Peru, Arkhangelsk, Russia, Ashkelon, Israel, Aurora, United States, Baia Mare, Romania, Bangalore, India and 70 more location s